TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: BMS-247550 in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically or cytologically confirmed advanced solid tumor that has failed standard therapy or for which no standard therapy exists No hematological malignancies allowed Measurable or evaluable disease Must have clinical or radiological evidence of disease No active brain metastases including evidence of cerebral edema by CT or MRI, or progression from prior imaging study, any requirement for steroids, or clinical symptoms of/from brain metastases~PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At least 3 months Hematopoietic: Absolute neutrophil count at least 2,000/mm3 Platelet count at least 100,000/mm3 Hemoglobin at least 9.0 g/dL Hepatic: Bilirubin no greater than 1.5 mg/dL AST/ALT no greater than 2.5 times upper limit of normal (ULN) Renal: Creatinine less than 1.5 times ULN Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception No preexisting peripheral neuropathy greater than grade 1 due to any cause No documented hypersensitivity reaction grade 2 or greater to prior paclitaxel or other therapy containing Cremophor EL No serious uncontrolled medical disorder or active infection that would preclude protocol therapy No dementia or altered mental status that would preclude compliance HIV negative~PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior immunotherapy No concurrent biologic therapy Chemotherapy: At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas, mitomycin, and doxorubicin HCl liposome) Prior taxanes allowed No more than 2 prior chemotherapy regimens in metastatic setting Prior adjuvant/neoadjuvant chemotherapy allowed No other concurrent chemotherapy Endocrine therapy: See Disease Characteristics No concurrent hormonal therapy (except hormone replacement therapy or medication to maintain castrate status) Radiotherapy: At least 4 weeks since prior radiotherapy No prior radiotherapy to greater than 25% of bone marrow No concurrent radiotherapy Surgery: No concurrent surgery Other: At least 4 weeks since other prior investigational agents No other concurrent experimental anticancer medications No other concurrent specific antitumor therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Indigo Naturalis in Treating Atopic Dermatitis Topically

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Between 6 and 65 years old, female or male.~2. Atopic dermatitis fulfilling the diagnostic criteria of Williams et al.~3. Atopic dermatitis involving \<40% of BSA. (Base on the BSA result of Screening)~4. An Investigator's Global Assessment (IGA) score of 2, 3 or 4 which corresponds to mild, moderate or severe disease. (Base on the IGA result of Screening)~5. Female patients of child-bearing age with negative pregnancy test at screening.~6. Female patients of child-bearing age that agree to continue using birth control measures approved by the investigator and agree not to lactate for the duration of the study.~7. Agree to only receive stable doses of an additive-free, basic bland emollient for at least 7 days before baseline (day0)~8. Willing to comply with study protocol and agree to sign an informed consent form.~Exclusion Criteria:~1. Having a history of topical or systematical hypersensitivity to indigo naturalis or its excipient (e.g. beeswax) in ointment~2. Undergoing phototherapy (e.g. UVB, PUVA) or systemic therapy (e.g. Immunosuppressive agents) within 30 days.~3. Having used topical therapy (e.g. topical corticosteroids) for dermatitis within 7 days before the first application of the study medication.~4. Having a significant concurrent disease, such as: significant abnormalities in hematology, severe uncontrolled metabolic syndrome (e.g., hypertension, diabetes mellitus, metabolic arthritis, hyperthyroidism), psychiatric disease, cancer or AIDS.~5. Having abnormal liver or renal function (AST/ALT \>3 x ULN, creatinine \>2.0 mg/dl).~6. Women who are lactating, pregnant or preparing to be pregnant.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Indigo naturalis ointment (Type: EXPERIMENTAL): 1. Form: ointment~2. Dose: each gram of ointment contains 200µg of indirubin~3. Dosing schedule: apply 0.5g of ointment per 10 x 10 dermatitis lesion twice daily
- Placebo (Type: PLACEBO_COMPARATOR): 1. Form: ointment~2. Dose: vehicle~3. Dosing schedule: apply 0.5g of ointment per 10 x 10 dermatitis lesion twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Selected Inclusion Criteria:~Parts A \& B (COMPLETED ENROLLMENT):~* Healthy male or female~* 18-55 years of age, inclusive~* At least 50 kg in weight~* BMI: 18.0-30.0 kg/m2, inclusive~Part C (COMPLETED ENROLLMENT):~* Male or female with atopic dermatitis~* 18-65 years of age, inclusive~* BMI between 18.0 (inclusive) and \<40.0 kg/m2~* Body surface area (BSA) with AD involvement ≥10%~* Eczema Area and Severity Index (EASI) score ≥12~* Validated Investigator's Global Assessment (vIGA) ≥3~* History of inadequate response to treatment with topical medications, such as corticosteroids or calcineurin inhibitors, or patients for whom topical treatments are otherwise medically inadvisable~Selected Exclusion Criteria:~Parts A \& B (COMPLETED ENROLLMENT):~* Use of tobacco products within 60 days prior to drug administration~* History of alcohol abuse or drug addiction~* Positive drug and alcohol screen~* Participation in a drug study within 60 days prior to drug administration~* Donation or loss of more than 100 mL of blood within 60 days prior to drug administration.~* Donation or loss of more than 1.5 liters of blood (for male subjects) / more than 1.0 liters of blood (for female subjects) in the 10 months prior to drug administration.~Part C (COMPLETED ENROLLMENT):~* Any serious and/or uncontrolled medical condition~* History of alcohol abuse or drug addiction~* Positive drug and alcohol screen

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- COMPLETED ENROLLMENT -- Single Dose Escalation Part A - active (Type: EXPERIMENTAL): Increasing doses of RPT193 will be administered to healthy volunteers
- COMPLETED ENROLLMENT -- Single Dose Escalation Part A - placebo (Type: PLACEBO_COMPARATOR): Matching placebo will be administered to healthy volunteers
- COMPLETED ENROLLMENT -- Multiple Dose Escalation Part B - active (Type: EXPERIMENTAL): Increasing doses of RPT193 will be administered once/day for 7 days to healthy volunteers
- COMPLETED ENROLLMENT -- Multiple Dose Escalation Part B - placebo (Type: PLACEBO_COMPARATOR): Matching placebo will be administered once/day for 7 days to healthy volunteers
- COMPLETED ENROLLMENT -- Expansion Part C - active (Type: EXPERIMENTAL): RPT193 will be administered daily for 28 days to patients with atopic dermatitis
- COMPLETED ENROLLMENT -- Expansion Part C - placebo (Type: PLACEBO_COMPARATOR): Matching placebo will be administered daily for 28 days to patients with atopic dermatitis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Skin and Muscle Parameters Using a Skin Sensor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males and Females age 18 and over~* Recent (post-operative day 0-90) skin surgery of the trunk,extremities, head or neck for minor skin problems resulting in sutured wounds or open granulating wounds.~* Otherwise good general health as assessed by the investigator~* The subject has the willingness and the ability to understand and provide informed consent for the use of their tissue and communicate with the investigator.~Exclusion Criteria:~* Under 18 years of age~* Pregnancy or Lactation~* Subjects who are unable to understand the protocol or to give informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Skin sensor on surgery side (Type: EXPERIMENTAL): Skin sensor will be placed on the side that had surgery. This is split-body, interventional, parallel-design study. All participants will have the skin sensor measured twice on their bodies: on the side with surgery and a contralateral, control site of the body.
- Skin sensor on non-surgery side (Type: ACTIVE_COMPARATOR): Skin sensor will be placed on the contralateral side from surgery site.This is split-body, interventional, parallel-design study. All participants will have the skin sensor measured twice on their bodies: on the side with surgery and a contralateral, control site of the body.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Combination of Pemetrexed and Irinotecan Every Two Weeks in Metastatic Colorectal Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of metastatic colorectal adenocarcinoma that is not amenable to curative therapy.~* Patient must have at least one unidimensionally measurable lesion.~* Prior radiation therapy to less than 25% of bone marrow. Radiation must be completed at least 4 weeks prior to study enrollment.~* Performance status 0 to 2~* Patient must have received 1 prior course of chemotherapy (Folfox regimen) for metastatic disease~Exclusion Criteria:~* Treatment with any drug within the last 30 days that has not received regulatory approval.~* Serious systemic disorder (cardiac or pulmonary disease, active infection)~* Documented brain metastases not amenable to surgery or unstable after radiation~* Inability or unwillingness to take folic acid or Vitamin B12 supplementation.~* Presence of fluid retention that can not be controlled by drainage.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pemetrexed + Irinotecan (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Potential Effect of Artemether - Lumefantrine and Malaria Drugs on Auditory Function

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria~* 12 years of age or older~* Accepts Healthy Volunteers~* P. falciparum parasitemia between 1,000 and 100,000 parasites/μl~* History of fever or presence of fever (temperature ≥ 37.5°C)~Exclusion Criteria~* Signs/symptoms of severe/complicated malaria~* Ingestion of various antimalarial drugs, or antibiotics in the previous 2 weeks to 2 months~* History of any drug-related hearing impairment~* Abnormal hearing function at study entry~* Exposure to sustained loud noises, by self-report, within the past 24 hours~* Present ear problems~* Pregnant or lactating (urine test for β-HCG) to be performed on any woman of child bearing age)~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- Artemether-lumefantrine (Coartem) (Type: EXPERIMENTAL): Artemether-lumefantrine (Coartem) tablets containing 20 mg artemether and 120 mg lumefantrine twice a day for 3 days, dosage dependent on body weight.
- Atovaquone-proguanil (Malarone) (Type: ACTIVE_COMPARATOR): Atovaquone-proguanil (Malarone) tablets containing 250 mg atovaquone and 100 mg proguanil hydrochloride once daily for 3 days, dosage dependent on body weight.
- Artesunate-mefloquine (Type: ACTIVE_COMPARATOR): Artesunate-mefloquine tablets containing 50 mg artesunate (Plasmotrim) and 250 mg mefloquine (Mephaquin). Artesunate 4 mg/kg/day (for 3 days) and mefloquine 25 mg/kg/day (days 2 and 3) total dose was given once daily dependent upon body weight.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Promotion of Coronary Collateral Function by Ivabradine-Induced Bradycardia in Patients With Coronary Artery Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \> 18 years old~2. 1- to 3-vessel stable coronary artery disease (CAD)~3. At least 1 stenotic lesion suitable for PCI~4. No Q-wave myocardial infarction in the area undergoing CFI measurement~5. Written informed consent to participate in the study~Exclusion Criteria:~1. Acute coronary syndrome~2. CAD treated best by surgical coronary bypass~3. Indications for BB treatment (heart failure, arrhythmias, \<3months post-infarct)~4. RHR \<60/min without any treatment~5. Sick sinus syndrome, sinuatrial block or \>2nd degree atrio-ventricular block~6. Atrial fibrillation~7. Inherited or acquired long-QT syndrome~8. Indwelling pacemaker~9. Severe hepatic or renal failure (creatinine clearance \<15ml/min)~10. Hypersensitivity against ivabradine or adjuvants~11. Pre-menopausal women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Collateral promotion; PCI after 6 months (Type: EXPERIMENTAL): None
- Collateral promotion; PCI at baseline (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Patient-controlled Sedation With Propofol and Remifentanyl for Endoscopic Retrograde Cholangiopancreatography (ERCP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* elective ERCP-patients~Exclusion Criteria:~* allergy to propofol or opioid;~* ASA-class (American Society of Anaesthesiology) greater than 3;~* inability to co-operate;~* drugs abuse.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Propofol infusion (Type: ACTIVE_COMPARATOR): Anaesthesiologist's managed intravenous infusion of propofol 10mg/ml
- Patient-controlled sedation (Type: ACTIVE_COMPARATOR): self-administration of propofol and remifentanil mixture during ERCP

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Multiple Ascending Dose Study of HTD1801 in Adults With Hypercholesterolemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Have given written informed consent~2. Males or females aged 18 to 70 years old at the time of first dosing~3. Have a body mass index (BMI) of \>25.0 and ≤ 45.0 kg/m2 at Screening~4. Have a documented history of hypercholesterolemia, defined as LDL-C ≥ 2.59 mmol/L~Exclusion Criteria:~1. The use of any anti-dyslipidemia agent within 28 days prior to dosing~2. History of a total cholesterol ≥ 10.35 mmol/L or triglyceride ≥ 11.3 mmol/L~3. History of a clinically significant cardiac arrhythmia or clinically significant abnormal ECG results at Screening~4. Significant peripheral or coronary vascular disease~5. Clinically significant abnormal blood pressure at Screening or Baseline, defined as supine blood pressure ≥160/100 mmHg, or ≤ 90/60 mmHg~6. Primary hypothyroidism (thyroid stimulating hormone \[TSH\] \> upper limit or normal \[ULN\] and free T4 \< lower limit of normal \[LLN\]), primary subclinical hypothyroidism (screening TSH \> ULN and free T4 within normal limits \[WNL\]), or secondary hypothyroidism (screening TSH \< LLN and free T4\< LLN) at Screening~7. Glucose-6-phosphate dehydrogenase (G6PD) deficiency

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- HTD1801 250 mg BID (Type: EXPERIMENTAL): Subjects received 500 mg/day HTD1801
- HTD1801 500 mg BID (Type: EXPERIMENTAL): Subjects received 1000 mg/day HTD1801
- HTD1801 1000 mg BID (Type: EXPERIMENTAL): Subjects received 2000 mg/day HTD1801
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Collect Blood Biomarker Samples From Participants With Chronic Hepatitis B (CHB) Who Received Treatment With Pegasys (Peginterferon Alfa-2a) ± Nucleoside/Nucleotide Analogue

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adults greater than or equal to (≥) 18 years of age~* CHB~* Previously enrolled in a Roche study and treated for CHB for ≥24 weeks with Peg-IFN ± nucleoside analogue (lamivudine or entecavir) or Peg-IFN ± nucleotide analogue (adefovir) and with ≥24 weeks post-treatment follow-up; or~* Treated in general practice for CHB with Peg-IFN according to standard of care and in line with the current Summary of Product Characteristics (SmPC)/local labeling who have no contraindication to Peg-IFN therapy as per local label and have been treated with Peg-IFN for ≥24 weeks and have ≥24 week post-treatment response available at the time of blood sample collection~Exclusion Criteria:~* Hepatitis A, hepatitis C, or human immunodeficiency virus (HIV) infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adult CHB Participants Treated With Peg-IFN Alfa-2a (Type: None): Adult participants with CHB infection, and who have completed at least 24 weeks of Peg-IFN alfa-2a with/without nucleoside analogue therapy and at least 24 weeks of follow-up, will be included. Participants will be recruited from Roche clinical trials or general practice; no treatment will be administered in this non-interventional study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Asthma Care With Alvesco® (Ciclesonide) in Primary Care in Adults - The ACCEPT-study (BY9010/CA-102)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Main inclusion criteria:~* Written informed consent~* 18 years or older with diagnosis of asthma for at least 6 months~* Clinically stable asthma at the time of study enrollment~* Clinical requirements for treatment with ICS as outlined in the Canadian Asthma Consensus Guidelines~* If patients are currently on ICS, the dose must be stable for 3 months and they must be willing to switch~Main exclusion criteria:~* On combination therapy (ICS + long acting beta-2-agonist) for asthma in the past 3 months or require combination therapy~* Severe asthma, one or more asthma exacerbations in the last 3 months requiring hospitalization or emergency room visit, or patients who have used systemic steroids more than 3 times in the past 6 months or who are currently using systemic steroids~* Mild asthma requiring short acting beta-2-agonists only~* Patients with a contraindication to ICS therapy~* Any other disease or medical condition requiring further clinical evaluation, which in the opinion of the Primary Care Practitioner may interfere with the clinical study or interfere with the diagnosis of asthma.~* Pregnancy, breast feeding, intention to become pregnant during the course of the study or lack of safe contraception in pre-menopausal women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Alvesco (Type: ACTIVE_COMPARATOR): Alvesco 320mcg / Alvesco 640mcg
- Usual Care (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dysport® Adult Upper Limb Spasticity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients - post stroke or brain injury~* Modified Ashworth Scale ≥ 2~* Ambulatory patients~Exclusion Criteria:~* Previous treatment with botulinum toxin of any type within 4 months prior to study entry for any condition~* Physiotherapy initiated less than 4 weeks before inclusion~* Previous surgery, alcohol, phenol in upper limb~* Neurological/neuromuscular disorders which may interfere with protocol evaluations

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Dysport 500 U (Type: EXPERIMENTAL): None
- Dysport 1000 U (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete